To investigate whether higher levels of ROS caused by arsenic sulfide treatment alters NFATc3 localization in cancer cells, we treated cells with 1 μM cyclosporine A (CsA, as a positive control) or 5 μM arsenic sulfide for 0, 0.5, 1 and 2 h. This evidence concerns the gene NFATC3 and cancer.